stockrow
Saturday 7 November 2026
Export SANA’s income statement to Excel — free account
Sana Biotechnology, Inc.
SANA Healthcare Biotechnology
- EPS
- +43.6%
- Free cash flow
- −5.46%
Quarter to June 2026, against a year earlier
2.37
0.03
+1.28%
Follow SANA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (13) | (138) | (285) | (356) | (269) | (283) | (267) | (244) | (212) | +51.6% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (13) | (131) | (285) | (356) | (269) | (283) | (267) | (244) | (212) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.07) | (26.67) | (21.92) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) | (0.76) | +45.4% | ||||||
| Cash flow | — | — | (0.07) | (17.44) | (10.60) | (1.51) | (1.54) | (1.30) | (0.97) | (0.57) | (0.45) | +34.3% | ||||||
| Capex | — | — | 0.00 | (5.33) | (1.83) | (0.18) | (0.11) | (0.10) | (0.14) | 0.00 | (0.01) | n/m | ||||||
| Free cash flow | — | — | (0.07) | (22.77) | (12.44) | (1.69) | (1.65) | (1.41) | (1.11) | (0.57) | (0.45) | +34.3% | ||||||
| Book value | — | — | 0.18 | (29.07) | (32.36) | 4.38 | 2.65 | 1.48 | 1.08 | 0.64 | 0.52 | +20.1% | ||||||
| Shares, m | — | — | 187 | 5 | 13 | 166 | 188 | 195 | 231 | 253 | 272 | +4.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (13) | (86) | (138) | (251) | (290) | (254) | (223) | (144) | (132) | +40.2% | |||||
| Capex | — | — | 0 | (26) | (24) | (30) | (21) | (20) | (33) | 0 | (2) | n/m | ||||||
| Free cash flow | — | — | (13) | (112) | (162) | (281) | (311) | (274) | (257) | (143) | (134) | +40.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 31 | 125 | 353 | 459 | 333 | 149 | 115 | 70 | 47 | +12.3% | |||||
| Net debt | — | — | (31) | (139) | (378) | (551) | (430) | (209) | (156) | (143) | (165) | +24.4% | ||||||
| Shareholders’ equity | — | — | 33 | (143) | (421) | 729 | 499 | 288 | 251 | 161 | 155 | +25.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (77.92) | (58.23) | (49.81) | (38.28) | (27.61) | (40.81) | (50.03) | (53.20) | (53.41) | +24.7 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (125.67) | (245.99) | (233.45) | (180.99) | (854.59) | 0.00 | (854.6) pt | ||||||
| ROE | — | — | 16.98 | 168.16 | 101.22 | (231.64) | (43.90) | (72.00) | (99.17) | (118.70) | (152.87) | (135.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 265 | 383 | 421 | 328 | 194 | 142 | — | (11.7%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Sana Biotechnology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LXRX Lexicon Pharmaceuticals, Inc. | $716.4M | — (loss-making) | — (loss-making) | −20.67% (below 0%: shrinking) | n/m | +66.10% (above 0%: growing) | 99.30% | (128.84%) | Compare |
| OABI OmniAb, Inc. | $704.5M | — (loss-making) | — (loss-making) | +78.34% (above 0%: growing) | n/m | +206.33% (above 0%: growing) | 92.26% | (409.92%) | Compare |
| SANA Sana Biotechnology, Inc. | $700.5M | — (loss-making) | — | — | n/m | −5.46% (below 0%: shrinking) | 0.00% | 0.00% | |
| CGEM Cullinan Therapeutics, Inc. | $695.0M | — (loss-making) | 4.8× | — | n/m | +33.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ATTO Attovia Therapeutics, Inc. | $684.8M | — | — | — | n/m | — | 100.00% | (4,845.11%) | Compare |
| DNA Ginkgo Bioworks Holdings, Inc. | $670.7M | — (loss-making) | — (loss-making) | −59.37% (below 0%: shrinking) | n/m | −16.38% (below 0%: shrinking) | 91.47% | (290.47%) | Compare |
| SLDB Solid Biosciences Inc. | $662.7M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −39.56% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AURA Aura Biosciences, Inc. | $657.5M | — (loss-making) | — | — | n/m | −56.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ACHV Achieve Life Sciences, Inc. | $656.0M | — (loss-making) | — | +54.44% (above 0%: growing) | n/m | −19.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $677.7M | — | — | −20.67% | — | −16.38% | 91.87% | (64.42%) |
Pay and ownership Proxy statement filed 24 April 2026
Ownership
Directors and executive officers, together
25.40%
Robert Nelsen
17.10%
Entities and individuals affiliated with ARCH Venture Partners
17.00%
Entities and individuals affiliated with FMR LLC
11.60%
Entities and individuals affiliated with Flagship Pioneering Funds
10.20%
Entities affiliated with BlackRock, Inc.
5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement